What are the 2026 guidelines for the acute and secondary management of stroke?

2026 Stroke Guidelines: Acute and Secondary Management

Acute Ischemic Stroke Management

The 2026 AHA/ASA guidelines represent the most current evidence-based approach to acute ischemic stroke, with key updates to thrombolytic therapy, endovascular treatment eligibility, and early complication management 1.

Immediate Evaluation and Treatment

Stroke must be treated as a life-threatening emergency requiring immediate evaluation to determine:

• Whether ischemic stroke is the cause of symptoms
• Eligibility for IV thrombolysis (rtPA/tenecteplase)
• Candidacy for endovascular thrombectomy

Airway, breathing, and circulation take priority, especially in seriously ill or comatose patients 2.

Thrombolytic Therapy

Intravenous rtPA (0.9 mg/kg; maximum 90 mg) remains strongly recommended for carefully selected patients within 3 hours of symptom onset 2. The 2026 guidelines incorporate new evidence on thrombolytic choice, with tenecteplase emerging as an effective alternative, particularly as bridging therapy before endovascular thrombectomy in large vessel occlusion (LVO) patients 3.

Extended Time Window (3-4.5 hours):

• Treatment is reasonable for patients >80 years old 4
• May be considered for mild strokes, though risk-benefit must be carefully weighed 4
• Benefit uncertain for very severe strokes (NIHSS >25) 4

Key Contraindications:

• Do NOT substitute streptokinase or other thrombolytic agents for rtPA 2
• Avoid if BP cannot be controlled below 185/110 mmHg pre-treatment or 180/105 mmHg during first 24 hours 5

Endovascular Thrombectomy

The 2026 guidelines update eligibility criteria for mechanical thrombectomy 1. Recent 2025 evidence shows:

• No benefit for routine endovascular thrombectomy in medium vessel occlusions (MeVO) - three randomized trials found no advantage over best medical therapy 3
• Tenecteplase before thrombectomy improves functional independence at 90 days compared to thrombectomy alone in LVO patients 3

Blood Pressure Management

Acute Phase (Ischemic Stroke):

Without reperfusion therapy: Avoid routine BP lowering unless SBP ≥220 mmHg or DBP ≥120 mmHg, then reduce by only ~15% within 24 hours 6.

With IV thrombolysis or thrombectomy: Maintain BP <185/110 mmHg pre-treatment and <180/105 mmHg during first 24 hours 5, 6.

Common pitfall: Overly aggressive BP lowering can worsen cerebral perfusion in acute ischemic stroke.

Antiplatelet Therapy

Aspirin 325 mg should be administered within 24-48 hours after stroke onset 5, 7. This provides modest benefit primarily through prevention of early recurrent stroke 5.

Critical Restrictions:

• Do NOT give aspirin or any antiplatelet agent within 24 hours of IV thrombolysis 5
• Aspirin is NOT a substitute for rtPA 5

Minor Stroke/High-Risk TIA:

For NIHSS ≤3 or ABCD2 ≥4: Initiate dual antiplatelet therapy (DAPT) with:

• Aspirin 81 mg + clopidogrel 75 mg daily
• Loading doses: aspirin 160-325 mg + clopidogrel 300-600 mg
• Start within 12-24 hours after excluding hemorrhage
• Continue for 21 days, then switch to single antiplatelet 8

Alternative regimen: Aspirin 75-100 mg + ticagrelor 90 mg twice daily for 30 days 8

Anticoagulation

Urgent anticoagulation is NOT recommended for acute ischemic stroke 5. Key points:

• Does not reduce early recurrent stroke risk 5
• Does not halt neurological worsening 5
• Increases risk of intracranial hemorrhage, especially in moderate-to-severe strokes 5
• Contraindicated within 24 hours of rtPA administration 5

Exception for atrial fibrillation: Individual patient data meta-analysis confirms that early direct oral anticoagulant (DOAC) initiation within 4 days reduces recurrent ischemic stroke without increasing symptomatic ICH 3.

Cerebral Edema and Increased Intracranial Pressure

• Corticosteroids are NOT recommended (Grade A) 2
• Osmotherapy and hyperventilation are recommended for deteriorating patients with increased ICP or herniation (Grade B) 2
• Surgical decompression of large cerebellar infarctions causing brainstem compression is recommended (Grade C) 2
• Decompressive hemicraniectomy for large hemispheric infarctions is life-saving but leaves severe residual impairment (Grade C) 2

Seizure Management

• Treat recurrent seizures as with any acute neurological condition 2
• Do NOT give prophylactic anticonvulsants to stroke patients without seizures 2

Intracerebral Hemorrhage (ICH) Management

Acute Blood Pressure Control

All major 2025 guidelines converge on rapid but carefully titrated SBP reduction toward approximately 140 mmHg 6. The 2025 individual patient data meta-analysis of 4 trials confirmed:

• Intensive BP lowering in acute ICH is safe and improves functional recovery 3
• Greatest benefit when started within 3 hours 3
• Avoid overshoot, large variability, and excessive early declines 6
• Particular caution when baseline SBP >220 mmHg 6

Preferred agents: Micro-infusion calcium channel blockers for acute parenteral therapy 6.

Long-term Management After ICH

Target BP <130/80 mmHg for secondary prevention 6. A 2025 trial showed that triple-pill combination therapy achieved BP control and reduced recurrent stroke after ICH 3.

Secondary Prevention (Chronic Phase)

Blood Pressure Targets

For ischemic stroke: Target <130/80 mmHg per AHA, ESH, and JSH guidelines 6. ESC prioritizes SBP 120-129 mmHg 6.

Preferred agents: Thiazide diuretics, ACE inhibitors, and angiotensin receptor blockers remain foundational 6.

Antiplatelet Therapy for Non-Cardioembolic Stroke

Long-term options include:

• Aspirin 81-325 mg daily
• Clopidogrel 75 mg daily
• Aspirin 25 mg + dipyridamole 200 mg twice daily 8

Novel Anticoagulation

For non-cardioembolic stroke: A 2025 phase 3 trial showed that asundexian (a novel factor XIa inhibitor) reduced ischemic stroke risk without increasing major bleeding 3.

Intracranial Atherosclerotic Disease (ICAD)

For moderate-to-high grade stenosis (50-99%):

• DAPT with aspirin + clopidogrel shows 54.4% relative risk reduction in microembolic signals 8
• High-dose statin therapy 8
• SBP target <140 mmHg 8
• At least moderate physical activity 8
• Angioplasty and stenting NOT recommended - DAPT is appropriate medical therapy 8

Systems of Care

• Comprehensive stroke unit care with rehabilitation should be provided to a broad spectrum of patients 2
• Mobile stroke units are cost-effective in high-volume systems 3
• Multidisciplinary outpatient team-based approach effectively controls BP, lipids, and vascular risk factors 9
• Voluntary quality monitoring programs improve adherence to evidence-based guidelines 9

Key Knowledge Gaps Identified in 2026

The guidelines highlight urgent research needs:

• Identifying MeVO subgroups that may benefit from EVT 3
• Role of adjunct intra-arterial thrombolysis after successful EVT 3
• Optimal imaging-based selection pathways across different stroke systems 3
• Effectiveness of DOACs versus antiplatelet therapy in noncardioembolic stroke 9
• Optimal DAPT combinations, timing, and duration 9